<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

MuScreen™ – the First In Vivo IO Syngeneic Screening Platform

Immunotherapeutics can be difficult to evaluate preclinically - in vitro cell-based screens usually used to quickly identify responsive cells and assess PD effects often fail in immuno-oncology, due to IO agents targeting the complex host immune system.